tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Neurocrine pullback despite ‘big quarter’ a buying opportunity, says RBC Capital
PremiumThe FlyNeurocrine pullback despite ‘big quarter’ a buying opportunity, says RBC Capital
12d ago
Neurocrine price target raised to $183 from $174 at Stifel
Premium
The Fly
Neurocrine price target raised to $183 from $174 at Stifel
12d ago
Neurocrine price target raised to $160 from $156 at RBC Capital
Premium
The Fly
Neurocrine price target raised to $160 from $156 at RBC Capital
12d ago
Neurocrine price target raised to $203 from $175 at Citi
PremiumThe FlyNeurocrine price target raised to $203 from $175 at Citi
12d ago
Neurocrine’s Strong Financial Performance and Growth Potential Justify Buy Rating
Premium
Ratings
Neurocrine’s Strong Financial Performance and Growth Potential Justify Buy Rating
12d ago
Neurocrine Biosciences Reports Strong Q3 2025 Growth
Premium
Company Announcements
Neurocrine Biosciences Reports Strong Q3 2025 Growth
12d ago
Neurocrine reports Q3 INGREZZA net product sales $687M
PremiumThe FlyNeurocrine reports Q3 INGREZZA net product sales $687M
13d ago
Neurocrine Biosciences’ New Study on MDD Treatment: What Investors Need to Know
Premium
Company Announcements
Neurocrine Biosciences’ New Study on MDD Treatment: What Investors Need to Know
14d ago
Neurocrine Biosciences Advances Pediatric CAH Treatment with New Study
Premium
Company Announcements
Neurocrine Biosciences Advances Pediatric CAH Treatment with New Study
14d ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100